UBS Asset Management Americas Inc. increased its position in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 3.7% during the second quarter, Holdings Channel reports. The fund owned 23,721 shares of the company’s stock after buying an additional 851 shares during the period. UBS Asset Management Americas Inc. owned approximately 0.09% of Five Prime Therapeutics worth $981,000 as of its most recent filing with the SEC.
Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its stake in Five Prime Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 944,434 shares of the company’s stock worth $38,372,000 after buying an additional 15,566 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Five Prime Therapeutics by 11.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,600,000 shares of the company’s stock worth $105,638,000 after buying an additional 275,000 shares during the last quarter. First Trust Advisors LP bought a new stake in Five Prime Therapeutics during the second quarter worth about $1,706,000. Schonfeld Strategic Advisors LLC bought a new stake in Five Prime Therapeutics during the first quarter worth about $411,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Five Prime Therapeutics by 6.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,245 shares of the company’s stock worth $3,277,000 after buying an additional 4,531 shares during the last quarter. Institutional investors own 86.43% of the company’s stock.
Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 47.2074 on Wednesday. The stock’s 50 day moving average price is $50.04 and its 200 day moving average price is $46.09. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 5.3096 and a beta of 4.46. Five Prime Therapeutics Inc. has a 12 month low of $27.76 and a 12 month high of $55.00.
Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The company had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. Five Prime Therapeutics had a return on equity of 69.59% and a net margin of 63.88%. Five Prime Therapeutics’s quarterly revenue was up 46.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.45) earnings per share. Equities research analysts anticipate that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current fiscal year.
A number of equities analysts have weighed in on the company. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a research note on Tuesday, July 12th. Jefferies Group set a $60.00 target price on Five Prime Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Finally, Leerink Swann restated an “outperform” rating and issued a $58.00 target price (up from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $52.33.
In related news, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the transaction, the director now directly owns 12,195 shares in the company, valued at $603,652.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $52.00, for a total value of $26,000.00. Following the transaction, the director now owns 500 shares in the company, valued at $26,000. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc. (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.